Abstract
Previous studies have shown that local angiogenic gene therapy acts, in part, by recruiting endothelial progenitor cells (EPCs) to ischemic tissue. Recent data indicate that patients with the most severe vascular disease may have insufficient or deficient EPCs and the poorest response to angiogenic therapy. Accordingly, we hypothesized that combining human CD34+ cell implantation with local vascular endothelial growth factor 2 (phVEGF2) gene therapy might overcome these deficiencies. The addition of VEGF2 to EPC cultures resulted in significant and dose-dependent decreases in EPC apoptosis. Phosphorylated Akt (p-Akt) was increased in VEGF2-treated EPCs. In vivo, myocardial infarction (MI) was induced by ligation of the left anterior descending coronary artery in 34 immunodeficient rats. The animals were then randomized to one of four treatment groups: cell therapy alone with human CD34+ cells; VEGF2 gene therapy alone; combination therapy with CD34+ cells plus phVEGF2; or CD34− cells and 50 μg empty plasmid. Four weeks after MI, animals treated with combination therapy showed improved fractional shortening, increased capillary density, and reduced infarct size compared with the other three groups. Combination therapy was also associated with an increased number of circulating EPCs 1 week after MI. Combined subtherapeutic doses of cell and gene therapy result in a significant therapeutic effect compared to monotherapy. This approach may overcome therapeutic failures (e.g. inability of certain patients to mobilize sufficient EPCs) and may also offer safety advantages by allowing lower dosing strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Asahara T et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964–967
Takahashi T et al. (1999) Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5: 434–438
Yanagisawa-Miwa A et al. (1992) Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257: 1401–1403
Isner JM et al. (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348: 370–374
Losordo DW et al. (2002) Phase 1/2 placebo-controlled, double-blind dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105: 2012–2018
Autiero M et al. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9: 936–943
Kawamoto A et al. (2001) Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103: 634–637
Kocher AA et al. (2001) Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7: 430–436
Kawamoto A et al. (2003) Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107: 461–468
Ii M et al. (2005) Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via “imported” nitric oxide synthase activity. Circulation 111: 1114–1120
Gnecchi M et al. (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11: 367–368
Tateishi-Yuyama E et al. (2002) Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360: 427–435
Kawamoto A et al. (2004) Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation 110: 1398–1405
Yamaguchi J et al. (2003) Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 107: 1322–1328
Yoon YS et al. (2005) Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest 115: 326–338
Hu J-S et al. (1997) A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial and smooth muscle cells. FASEB J 11: 498–504
Witzenbichler B et al. (1998) Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 153: 381–394
Dimmeler S et al. (2001) HMG-CoA-reductase inhibitors (statins) increase endothelial progenitor cells via the P13 kinase/Akt pathway. J Clin Invest 108: 391–397
Murasawa S et al. (2002) Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation 106: 1133–1139
Vasa M et al. (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: E1–E7
Hill JM et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593–600
Heeschen C et al. (2004) Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109: 1615–1622
Valgimigli M et al. (2004) CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 110: 1209–1212
Iwaguro H et al. (2002) Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105: 732–738
Shintani S et al. (2001) Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103: 2776–2769
Kalka C et al. (2000) Vascular endothelial growth factor165 gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 86: 1198–1202
Losordo DW and Dimmeler S (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 109: 2692–2697
Werner N et al. (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353, 999–1007
Acknowledgements
We acknowledge the assistance of Mickey Neely and Deirdre Costello in the preparation of this manuscript. S Shintani was supported by the Banyu Fellowship Award in Cardiovascular Medicine sponsored by Banyu Pharmaceutical Co. and The Merck Company Foundation. This work was supported by National Institutes of Health grants (HL-53354, HL57516, HL-63414, HL-80137, HL-66957 to DWL).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
DW Losordo has received research grants and consulting fees from Baxter Healthcare, Boston Scientific, Cordis, Curis, Corautus Genetics, Amgen, Genzyme, and Anormed.
Rights and permissions
About this article
Cite this article
Shintani, S., Kusano, K., Ii, M. et al. Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI. Nat Rev Cardiol 3 (Suppl 1), S123–S128 (2006). https://doi.org/10.1038/ncpcardio0430
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0430
This article is cited by
-
The peripheral blood mononuclear cells versus purified CD34+ cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis—a randomized single-blinded non-inferiority trial
Stem Cell Research & Therapy (2022)
-
Strategies to Enhance the Effectiveness of Adult Stem Cell Therapy for Ischemic Heart Diseases Affecting the Elderly Patients
Stem Cell Reviews and Reports (2016)
-
Myocardial transfection of hypoxia-inducible factor-1α and co-transplantation of mesenchymal stem cells enhance cardiac repair in rats with experimental myocardial infarction
Stem Cell Research & Therapy (2014)
-
Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials
Angiogenesis (2012)
-
Preconditioning and Stem Cell Survival
Journal of Cardiovascular Translational Research (2010)